Results 41 to 50 of about 33,791,512 (292)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Induces Calcitonin Gene-Related Peptide (CGRP)-I and Procalcitonin (Pro-CT) Production in Human Adipocytes [PDF]

, 2011
Context: Increased plasma levels of glucose-dependent insulinotropic polypeptide (GIP), calcitonin CT gene-related peptide (CGRP)-I, and procalcitonin (Pro-CT) are associated with obesity.
Beat Müller, Tanja Radimerski, Ralph Peterli, Ulrich Keller, Christ-Crain, Mirjam, Daniel M. Frey, Timper, Katharina, Frey, Daniel M., Mirjam Christ-Crain, Jean Grisouard, Häring, Andreas, Zulewski, Henryk, Keller, Ulrich, Grisouard, Jean, Katharina Timper, Henryk Zulewski, Radimerski, Tanja, Müller, Beat, Kaethi Dembinski, Dembinski, Kaethi, Andreas Häring, Peterli, Ralph   +21 more
core   +1 more source

Safety and Efficacy of GLP‐1 Receptor Agonists in Adults With Epilepsy, Obesity, and Type 2 Diabetes

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Managing obesity in patients with epilepsy is complicated by the weight‐gaining properties of essential antiseizure medications (ASMs) such as valproate and pregabalin. We evaluated the safety and efficacy of initiating glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) in this population.
Hyoshin Son, Inyoung Hwang, Sang Won Lee, Yun Kim   +3 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes

Journal of Diabetes
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac, Philippa Trevella, Elif I. Ekinci   +2 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

EVIDENCE OF THE INFLUENCE OF GLUCAGON-LIKE PEPTIDE ANALOGS IN INFLAMMATORY BOWEL DISEASE: A SCOPING REVIEW [PDF]

Arquivos de Gastroenterologia
Background: Inflammatory bowel disease is a chronic, immune-mediated condition characterized by relapsing intestinal inflammation and progressive tissue damage.
Lucas Dalvi Armond REZENDE, Camila ADOUR, Gabriel Confalonieri BERTOLDI, Marco Antônio Oliveira BRITO, Flávia Lúcia CONCEIÇÃO, Mariana Poltronieri PACHECO   +5 more
doaj   +2 more sources

Charting Endocrine Progenitors Across Species and Organs

Advanced Science, EarlyView.
Endocrine progenitors give rise to the hormone‐producing cells of the pancreas and intestine. Using single‐cell multiomics and proteomics, this study compares these progenitors across species, systems, and organs, mapping the conserved and species‐specific gene regulatory networks that guide their formation.
Changying Jing, Michael Sterr, Özüm Sehnaz Caliskan, Lama Saber, Nicole Katarina Rogers, Samuel Ogden, Kei Kozawa, Christos Karampelias, Jessica Jaki, Aimée Bastidas‐Ponce, Falk Janos Farkas, Oliver Czarnecki, Osvaldo Rodrigues Pereira, Perla Cota, Valerie Vandenbempt, Diego Balboa, Anika Böttcher, Natalie Krahmer, Mohammad Lotfollahi, Julie B. Sneddon, Heiko Lickert, Mostafa Bakhti   +21 more
wiley   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +2 more sources

Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice

Journal of Diabetes Investigation
Aims/Introduction Imeglimin is a recently approved oral antidiabetic agent that improves insulin resistance, and promotes insulin secretion from pancreatic β‐cells.
Osamu Kikuchi, Yuichi Ikeuchi, Masaki Kobayashi, Yoko Tabei, Hiromi Yokota‐Hashimoto, Tadahiro Kitamura   +5 more
doaj   +1 more source

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents

Neural Regeneration Research, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj   +1 more source

Engineered Brain‐Targeted Exosomes Delivering FGF1 for Sustained Glycemic Regulation and Multitarget Neurovascular Protection in Diabetic Stroke

Advanced Science, EarlyView.
ABSTRACT Diabetic stroke is characterized by a hyperglycemic and pro‐inflammatory microenvironment that exacerbates neurovascular dysfunction. However, the blood–brain barrier (BBB) remains a formidable obstacle, restricting the delivery of most therapeutic molecules.
Bixin Shen, Chengxiang Zhang, Junhui Wang, Xichong Zhong, Shihao Chen, Xue Wang, Xiaokun Li, Li Lin   +7 more
wiley   +1 more source